Research assistance

We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 

Matching geography

Reports matching your search in:
 
 

Join Alert Me now!

Receive bi-weekly email alerts on new market research

Sign up today!
 

Autoimmune: market research reports

1594

Autoimmune diseases arise from an overactive immune response of the body against substances and tissues normally present in the body. In these disorders, instead of protecting the body, the body attacks itself. The immune system mistakes some part of the body as a pathogen and creates a defense. This may be restricted to certain organs (e.g. in chagas disease) or involve a particular tissue in different places (e.g.
Goodpasture's disease which may affect the basement membrane in both the lung and the kidney). The treatment of autoimmune diseases is typically with immunosuppression—medication which decreases the immune response. Immunosuppressants are many and there is considerable research and development going on in this area.

Classification of autoimmune disorders is still somewhat controversial, but the following criteria is generally accepted: Direct evidence from transfer of pathogenic antibody or pathogenic T cells, indirect evidence based on reproduction of the autoimmune disease in experimental animals, and circumstantial evidence from clinical clues

Arthritis is among the most common autoimmune disorders. Arthritis is joint inflammation The major complaint by individuals who have arthritis is joint pain. Pain is often a constant and may be localized to the joint affected. There are over one hundred forms different forms The most common form, osteoarthritis (degenerative joint disease) is a result of trauma to the joint, infection of the joint, or age. Other arthritis forms are rheumatoid arthritis, psoriatic arthritis, and related autoimmune diseases. Septic arthritis is caused by joint infection. Treatment options vary depending on the type of arthritis and include physical therapy, exercise and weight control, bracing, medications. Surgery may be required in some changes.

RSS Feeds

Autoimmune market research reports and industry analysis

< prev 1  2  3  4  5  6  7  next >
Acquired (Autoimmune) Hemolytic Anemia – Pipeline Review, H2 2012
11/28/2012 | published by: Global Markets Direct
... the therapeutic development for Acquired (Autoimmune) Hemolytic Anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acquired (Autoimmune) Hemolytic Anemia. ...  |  more...
$2,000.00
Chronic Plaque Psoriasis Global Clinical Trials Review, H2, 2012
10/31/2012 | published by: GlobalData
... provides elemental information and data relating to the clinical trials on Chronic Plaque Psoriasis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the ...  |  more...
$2,500.00
Chronic Plaque Psoriasis – Pipeline Review, H2 2012
10/31/2012 | published by: Global Markets Direct
... development for Chronic Plaque Psoriasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis. Chronic Plaque Psoriasis - ...  |  more...
$2,000.00
Autologous Stem Cell and Non-Stem Cell Based Therapies Market (2012-2017) (Neurodegenerative, cardiovascular, cancer & autoimmune, skin and infectious diseases)
10/26/2012 | published by: MarketsandMarkets
... as next pillar or advancement in medical care. Growth of the market is very rapid especially in regulatory approvals, applications areas and rapid improvements in efficacy of treatment; it has enormous advantages over allogenic stem ...  |  more...
$4,650.00
Dermatology Therapeutics Market to 2018 - Novel Biologics Targeting Interleukin-17 Receptor Presents New Options in Psoriasis Treatment
10/15/2012 | published by: GBI Research
... - Novel Biologics Targeting Interleukin-17 Receptor Presents New Options in Psoriasis Treatment”. The report provides insights into the dermatology therapeutics market including market forecasts up to 2018. It provides an in-depth analysis of the major ...  |  more...
$3,500.00
Moderate Psoriasis – Pipeline Review, H2 2012
9/25/2012 | published by: Global Markets Direct
... Moderate Psoriasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Moderate Psoriasis. Moderate Psoriasis - Pipeline Review, Half Year is ...  |  more...
$2,000.00
Severe Psoriasis – Pipeline Review, H2 2012
9/25/2012 | published by: Global Markets Direct
... Severe Psoriasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Severe Psoriasis. Severe Psoriasis - Pipeline Review, Half Year is ...  |  more...
$2,000.00
Systemic Lupus Erythematosus – Pipeline Review, H2 2012
8/31/2012 | published by: Global Markets Direct
... the therapeutic development for Systemic Lupus Erythematosus, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus. 'Systemic Lupus ...  |  more...
$2,000.00
Psoriasis – Pipeline Review, H2 2012
8/31/2012 | published by: Global Markets Direct
... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psoriasis. 'Psoriasis - Pipeline Review, H2 2012' is built using data and information ...  |  more...
$2,000.00
Autoimmune Disorders – Pipeline Review, H2 2012
8/31/2012 | published by: Global Markets Direct
... for Autoimmune Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Autoimmune Disorders. 'Autoimmune Disorders - Pipeline Review, H2 2012' ...  |  more...
$2,500.00
Intravenous Immunoglobulin (IVIg)
8/1/2012 | published by: Global Industry Analysts
... for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 26 companies including many key and niche players such as Baxter International Inc., Beijing Tiantan Biological ...  |  more...
$4,450.00
Psoriasis Pipeline Perspectives Report - Intracellular Signaling Blockers
7/1/2012 | published by: Pharmspective
... are being actively pursued by manufacturers. Psoriasis Pipeline Perspectives Reports provide a comprehensive assessment of the drugs in development for Psoriasis by pathway target and mechanism of action. Pipeline Analysis by Pathway Target and Mechanism ...  |  more...
$1,500.00
Psoriasis Pipeline Perspectives Report
7/1/2012 | published by: Pharmspective
... are being actively pursued by manufacturers. Psoriasis Pipeline Perspectives Reports provide a comprehensive assessment of the drugs in development for Psoriasis by pathway target and mechanism of action. Pipeline Analysis by Pathway Target and Mechanism ...  |  more...
$8,500.00
Psoriasis Pipeline Perspectives Report - Direct Inflammatory Cytokine Blockers
7/1/2012 | published by: Pharmspective
... are being actively pursued by manufacturers. Psoriasis Pipeline Perspectives Reports provide a comprehensive assessment of the drugs in development for Psoriasis by pathway target and mechanism of action. Pipeline Analysis by Pathway Target and Mechanism ...  |  more...
$1,500.00
Psoriasis Pipeline Perspectives Report - T-cell Activation Blockers
7/1/2012 | published by: Pharmspective
... are being actively pursued by manufacturers. Psoriasis Pipeline Perspectives Reports provide a comprehensive assessment of the drugs in development for Psoriasis by pathway target and mechanism of action. Pipeline Analysis by Pathway Target and Mechanism ...  |  more...
$1,500.00
Psoriasis Pipeline Perspectives Report - T-cell Migration Blockers
7/1/2012 | published by: Pharmspective
... are being actively pursued by manufacturers. Psoriasis Pipeline Perspectives Reports provide a comprehensive assessment of the drugs in development for Psoriasis by pathway target and mechanism of action. Pipeline Analysis by Pathway Target and Mechanism ...  |  more...
$1,500.00
Psoriasis Pipeline Perspectives Report - Inflammatory Cytokine Blockers
7/1/2012 | published by: Pharmspective
... are being actively pursued by manufacturers. Psoriasis Pipeline Perspectives Reports provide a comprehensive assessment of the drugs in development for Psoriasis by pathway target and mechanism of action. Pipeline Analysis by Pathway Target and Mechanism ...  |  more...
$1,500.00
Psoriasis Market Info™ - Updated for 2012
5/1/2012 | published by: Drug Market Info
... relevant data on this disease and the overall market value — $1.8+ billion in 2010. The Psoriasis market is expected to grow significantly in the future, largely due to the chronic nature of the disease ...  |  more...
$4,950.00
Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments
4/30/2012 | published by: GBI Research
... its latest research “Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments”, which provides insights into autoimmune disease therapeutics ...  |  more...
$3,500.00
Psoriasis Global Clinical Trials Review, H1, 2012
4/30/2012 | published by: GlobalData
... to the clinical trials on Psoriasis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of ...  |  more...
$1,000.00
Treatment Algorithms: Psoriasis – Prescribing trends mirror guidelines
2/21/2012 | published by: Datamonitor
... patients. This trend is expected to continue over the next decade, as physicians gain clinical experience with these agents. Features and benefits Enhance understanding of patient flow and estimate the size of the psoriasis patient ...  |  more...
$7,600.00
Endpoints - Clinical Trials in Autoimmune Disorders - Multiple Primary and Secondary Endpoints are Increasingly Being Applied to Ensure Success
2/14/2012 | published by: GBI Research
... Clinical Trials in Autoimmune Disorders - Multiple Primary and Secondary Endpoints are Increasingly Being Applied to Ensure Success” which provides an insight into different endpoints used in clinical trials in autoimmune disorders. The report examines ...  |  more...
$3,500.00
Liver Disease Treatments: The Global Market
1/1/2012 | published by: BCC Research
... stagnant at $12.4 billion. Estimated sales in 2011 a projected $12 billion (excluding protease inhibitors). The market is expected to rise at a CAGR of 3.3% and reach nearly $14.2 billion by 2016. The U.S. ...  |  more...
$5,450.00
Celiac Disease - Pipeline Assessment and Market Forecasts to 2019
12/5/2011 | published by: GlobalData
... essential source of information and analysis on the global Celiac Disease Therapeutics market. The report identifies the key trends shaping and driving the global Celiac Disease Therapeutics market. The report also provides insights on the ...  |  more...
$3,500.00
Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market
12/1/2011 | published by: GBI Research
... research “Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market” which provides insights about monoclonal antibodies sales forecasts until 2017. Monoclonal ...  |  more...
$3,500.00
< prev 1  2  3  4  5  6  7  next >